Boston Scientific Q4 revenue slightly beats expectations

Boston Scientific

04/02/2026 11:38

Overview

Medical technology firm's Q4 revenue slightly beat analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company initiated U.S. launch of SEISMIQ IVL System for peripheral artery disease

Outlook

Boston Scientific estimates full-year 2026 net sales growth of 10.5% to 11.5%

Company expects first-quarter 2026 adjusted EPS between $0.78 and $0.80

Boston Scientific forecasts organic sales growth of 10.0% to 11.0% for 2026

Result Drivers

CARDIOVASCULAR GROWTH - Cardiovascular segment reported 18.2% sales growth, contributing significantly to overall revenue increase

REGIONAL SALES - U.S. sales grew 17%, leading regional performance, followed by strong growth in APAC and Emerging Markets

PRODUCT DISCONTINUATION - Discontinued sales of ACURATE neo2 and ACURATE Prime Aortic Valve Systems, impacting sales figures

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$5.29 bln
$5.28 bln (26 Analysts)
Q4 Adjusted EPS
Beat
$0.80
$0.78 (26 Analysts)
Q4 EPS
$0.45
Q4 Net Income
$672 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 34 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Boston Scientific Corp is $124.50, about 35.9% above its February 3 closing price of $91.62

The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 30 three months ago

Press Release: ID:nPn2qBB38a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)